GeoVax Secures $5 Million in Registered Direct Offering to Advance Biotechnology Initiatives
GeoVax Labs, Inc. has entered into a securities purchase agreement to raise approximately $5 million in gross proceeds, bolstering its financial position to further develop immunotherapies and vaccines against cancer and infectious diseases.
Read the full story




























